Fig. 2
From: Chemo-immunotherapy improves long-term survival in a preclinical model of MMR-D-related cancer
Treatment scheme. Mice received prophylactic or therapeutic applications of the vaccine, chemotherapy or a combination of both. The vaccine was prepared from an MLH1−/−-derived allograft. Immune monitoring as well as assessment of general behavior was done routinely during vaccination and at the experimental endpoint. Prior to therapy, mice underwent in vivo PET/CT imaging to confirm gastrointestinal tumorigenesis. Ex vivo analyses were done as described